Medicus Pharma announces clinical data on Teverelix

Medicus Pharma (MDCX) announces that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology, AACE, Annual Meeting 2026, to be held April 22-24 in Las Vegas, Nevada. Phase 1 Results: Rapid suppression of LH and FSH within 24 hours of dosing; Dose-dependent and reversible estradiol suppression, with multiple participants achieving levels within the clinically relevant Barbieri window, a range associated with symptom control while mitigating bone loss risk; Sustained pharmacodynamic activity, with hormone suppression lasting up to two to three weeks following a single injection at higher doses; Stable bone turnover markers, suggesting no evidence of short-term bone loss; Favorable safety profile, with no drug-related serious adverse events and only mild-to-moderate treatment-emergent adverse events reported. Additionally, the SkinJect Phase 2 Program on Track for Near-Term Data Readout